Article Per Year (5 Year)
p-Index From 2021 - 2026
0.23
P-Index
This Author published in this journals
All Journal Cermin Dunia Kedokteran Cermin Dunia Kedokteran
Johan Indra Lukito
Medical Department, PT. Kalbe Farma Tbk. Jakarta, Indonesia
Health Professions Medicine & Pharmacology Public Health

Published : 21 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 21 Documents
Search

 1   2   3 
Tinjauan atas Glucagon-like Peptide-1 Receptor Agonist Johan Indra Lukito
Cermin Dunia Kedokteran Vol 47 No 6 (2020): Kardiologi & Pediatri
Publisher : PT Kalbe Farma Tbk.

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.55175/cdk.v47i6.628

Abstract

GLP-1 receptor agonist secara struktur mirip hormon alami GLP-1 yang memiliki efek incretin, namun degradasinya dapat dicegah oleh DPP-4. Saat ini terdapat 8 jenis yang terdiri dari exenatide, exenatide ER, liraglutide, albiglutide, dulaglutide, lixisenatide, semaglutide injeksi, dan semaglitode oral. GLP-1 receptor agonist merupakan pilihan pengobatan DM tipe 2 baik sebagai tambahan maupun monoterapi. The GLP-1 receptor agonist is structurally similar to the natural hormone GLP-1 which has an incretin effect but prevented from breakdown by DPP-4. There are currently 8 types of GLP-1: exenatide, exenatide ER, liraglutide, albiglutide, dulaglutide, lixisenatide, injection semaglutide, and oral semaglutide. GLP-1 receptor agonist is an option for the treatment of type 2 DM both as adjunctive and as monotherapy.
Co-Authors